Figure 6.

GIPR activation had no effect on peripheral inflammation and glucose level. Systematic administration of D-Ala²-GIP (A, B) (n = 5 in control and CFA+Pro³+D-Ala² groups, n = 6 in CFA and CFA+D-Ala² groups) or ACC local injection of D-Ala²-GIP (C, D) (n = 11 in CFA group, n = 12 in other groups) did not reduce edema in CFA-injected hindpaw. GIPR knockdown did not reduce the footpad thickness in CFA-injected hindpaws (E, F) (n = 12 per group). There was no distinguished difference in the level of serum IL-1β (G) (n = 11 in CFA+D-Ala² group, n = 12 in other groups) among the groups. D-Ala²-GIP or Pro³-GIP had no evident effect on the blood glucose level (H) (n = 7 in control, CFA+D-Ala² and D-Ala² groups; n = 6 in CFA and Pro³ groups; n = 5 in CFA+Pro³+D-Ala² group). Totally, 155 mice were used for statistics in this figure. NC means Negative Control; GIPR-KD means GIPR knockdown; D-Ala² means D-Ala²-GIP; Pro³ means Pro³-GIP. ^*** p < 0.001, ^**** p < 0.0001.